Global Irritable Bowel Syndrome (IBS) Market Growth (Status and Outlook) 2023-2029

Global Irritable Bowel Syndrome (IBS) Market Growth (Status and Outlook) 2023-2029

Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.

LPI (LP Information)' newest research report, the “Irritable Bowel Syndrome (IBS) Industry Forecast” looks at past sales and reviews total world Irritable Bowel Syndrome (IBS) sales in 2022, providing a comprehensive analysis by region and market sector of projected Irritable Bowel Syndrome (IBS) sales for 2023 through 2029. With Irritable Bowel Syndrome (IBS) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Irritable Bowel Syndrome (IBS) industry.

This Insight Report provides a comprehensive analysis of the global Irritable Bowel Syndrome (IBS) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Irritable Bowel Syndrome (IBS) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Irritable Bowel Syndrome (IBS) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Irritable Bowel Syndrome (IBS) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Irritable Bowel Syndrome (IBS).

The global Irritable Bowel Syndrome (IBS) market size is projected to grow from US$ 4634.2 million in 2022 to US$ 12750 million in 2029; it is expected to grow at a CAGR of 15.6% from 2023 to 2029.

North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.

This report presents a comprehensive overview, market shares, and growth opportunities of Irritable Bowel Syndrome (IBS) market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

IBS-D Drug

IBS-C Drug

Others

Segmentation by application

Women

Men

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Bausch Health

Allergan

Takeda

Sucampo Pharmaceuticals (Mallinckrodt)

Sebela Pharmaceuticals Inc

Astellas Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.